Drug Profile
Gallium-68 NeoBOMB1 - Advanced Accelerator Applications
Alternative Names: 68Ga-NeoBOMB1; [68Ga]Ga-NeoBLatest Information Update: 12 Feb 2024
Price :
$50
*
At a glance
- Originator Erasmus University Rotterdam; National Center for Scientific Research Demokritos
- Developer Advanced Accelerator Applications; Erasmus University Rotterdam
- Class Imaging agents; Neuropeptides; Organometallic compounds; Peptides; Radioisotopes; Radiopharmaceutical diagnostics; Radiopharmaceuticals
- Mechanism of Action Bombesin receptor antagonists; Ionising radiation emitters; Neuropeptide receptor antagonists; Positron-emission tomography enhancers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Phase II Breast cancer
- Phase I/II Gastrointestinal stromal tumours; Solid tumours
- No development reported Colorectal cancer; Non-small cell lung cancer; Prostate cancer; Small cell lung cancer
Most Recent Events
- 08 Feb 2024 Novartis Pharmaceuticals plans a phase I/II trial for Breast cancer (Combination therapy, Metastatic disease, Second-line therapy or greater), in May 2024 (NCT06247995) (EudraCT2023-506717-21)
- 06 Oct 2023 Phase-I clinical trials in Breast cancer (Combination therapy, Metastatic disease, Late-stage disease, Second-line therapy or greater, Diagnosis) in Portugal (IV) (NCT05870579)
- 23 May 2023 Novartis Pharmaceuticals plans a phase Ib trial for Breast cancer (Diagnosis, Combination therapy, Metastatic disease, Second-line therapy or greater, last stage disease) (IV) (NCT05870579)